AbbVie gets USFDA nod for EPKINLY to treat adult patients with relapsed or refractory Diffuse Large B-Cell Lymphoma Ruchika Sharma20 May 2023 11:30 AM ISTDLBCL is a type of aggressive, fast-growing non-Hodgkin's lymphoma, a cancer that develops in the lymphatic system and affects B cells, a type of...
AbbVie plan to withdraw accelerated nods of Imbruvica in US for patients with certain types of blood cancer Ruchika Sharma7 April 2023 3:30 PM ISTIMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
AbbVie trims profit forecasts on IPRnD expenses Ruchika Sharma7 April 2023 2:30 PM ISTUnited States: AbbVie Inc has lowered its full-year and first-quarter profit expectations, citing a $150 million hit from acquired in-process...
USFDA refuses to approve AbbVie Parkinson's disease therapy ABBV-951, seeks more information Ruchika Sharma23 March 2023 12:15 PM ISTThe US health regulator has not sought additional efficacy and safety trials, the company said, adding it plans to resubmit the marketing application...
AbbVie gets positive EMA committee opinion for Upadacitinib to treat adults with moderate to severe Crohn's disease Ruchika Sharma28 Feb 2023 1:30 PM ISTDiscovered and developed by AbbVie scientists, upadacitinib is a selective and reversible Janus Kinase (JAK) inhibitor.
Cigna expects revenue gains from launches of Humira biosimilars Ruchika Sharma7 Feb 2023 11:44 AM ISTCigna's PBM unit has both Humira and Amgen's Amjevita on its list of covered drugs.
Eli Lilly, AbbVie exit UK drug pricing agreement Ruchika Sharma17 Jan 2023 2:30 PM ISTBengaluru: Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on...
AbbVie raises sales outlook of Skyrizi, Rinvoq to USD 17.5 billion in 2025 MD Bureau13 Jan 2023 2:26 PM ISTThe two drugs Skyrizi and Rinvoq are part of AbbVie's long term growth strategy to offset Humira's loss of exclusivity.
AbbVie to exit leading US drug industry trade group Ruchika Sharma17 Dec 2022 10:00 AM ISTAbbVie said it regularly evaluated its memberships with industry trade associations and decided not to renew with select trade associations, without...
AbbVie, Teva finalize USD 6.6 billion US opioid settlements Ruchika Sharma24 Nov 2022 4:27 PM ISTUS: Teva Pharmaceutical Industries Ltd and AbbVie Inc have finalized the terms of settlements worth more than $6.6 billion to resolve...
AbbVie receives EMA Committee positive opinion for Crohn's Disease treatment Risankizumab Ruchika Sharma21 Sept 2022 3:30 PM ISTSKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit.
AbbVie to pay up to USD 2.37 billion to resolve US opioid claims Ruchika Sharma31 July 2022 2:30 PM ISTNew Delhi: AbbVie Inc has agreed to pay up to $2.37 billion to resolve thousands of U.S. lawsuits against its Allergan unit over the marketing of...
